Biogen Inc. (BIIB)

261.22 -4.93 (-1.85%) At close: 04:00PM EDT

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 9,610

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael R. McDonnell CPA	Exec. VP & CFO	1.86M	N/A	1964
Ms. Susan H. Alexander Esq.	Exec. VP, Chief Legal Officer & Sec.	1.79M	N/A	1957
Mr. Christopher A. Viehbacher	Pres, CEO & Director	N/A	N/A	1960
Ms. Robin C. Kramer	Sr. VP & Chief Accounting Officer	N/A	N/A	1966
Ms. Nicole Murphy	Head of Pharmaceutical Operations & Technology	N/A	N/A	N/A
Mr. Michael Hencke	Head of Investor Relations	N/A	N/A	N/A
Ms. Natacha Gassenbach	Chief Communication Officer & Head of Corp. Affairs	N/A	N/A	N/A
Dr. Ginger Gregory	Exec. VP & Chief HR Officer	N/A	N/A	1968
Dr. Anabella Villalobos Ph.D.	Head of Biotherapeutics & Medicinal Sciences	N/A	N/A	1959
Dr. Mahalakshmi Radhakrishnan M.D.	Chief Medical Officer & Group Sr. VP	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Biogen Inc.’s ISS governance QualityScore as of 1 February 2023 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.